Replimune Group is awaiting a final United States Food and Drug Administration decision on RP1, its intratumoral oncolytic immunotherapy for advanced melanoma, after an external advisory committee voted 10 to three that the efficacy findings from the IGNYTE study were evaluable and clinically meaningful.
The agency had assigned August 2, 2026, as the target action date for the resubmitted biologics licence application. No final decision had been publicly announced by August 4, leaving patients, physicians and biotechnology investors assessing whether the additional time reflects negotiations over the indication, post-approval commitments or a potential third complete response letter.
Replimune is seeking accelerated approval for RP1, also known as vusolimogene oderparepvec, in combination with Bristol Myers Squibb’s nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed during or after an anti-PD-1-containing treatment.
The advisory vote substantially strengthened the company’s position after FDA reviewers argued that the single-arm IGNYTE study could not reliably separate RP1’s effect from the contribution of nivolumab. The panel’s support does not bind the regulator, however, and the scientific dispute identified in the briefing documents remains unresolved.
Why is the Replimune RP1 FDA decision still attracting intense investor attention?
RP1 has become a high-profile test of how much regulatory flexibility should be applied to therapies for patients with advanced cancer and limited treatment options.
The application has already received two complete response letters. The FDA initially rejected it in July 2025 after concluding that IGNYTE was not an adequate and well-controlled investigation capable of providing substantial evidence of effectiveness. A resubmission was rejected again in April 2026, after which Replimune continued discussions with the agency and submitted another response that received an expedited Class 1 review.
The July 30 advisory committee meeting produced the first decisive regulatory outcome in Replimune’s favour. Committee members considered whether the IGNYTE response results could be reliably interpreted and whether the observed tumour reductions represented clinically meaningful activity attributable to RP1. They ultimately voted 10 to three in support of the dataset.
Retail discussion subsequently shifted from whether RP1 had any realistic approval pathway to why the FDA had not issued its decision by the target date. Stocktwits reported mixed sentiment, with some participants interpreting the delay as possible label negotiations and others warning that another rejection remained possible. That speculation is not evidence of the agency’s intentions, but it illustrates why the story has become a major short-term biotechnology catalyst.
What is RP1 and how is the oncolytic virus designed to attack melanoma?
RP1 is based on an engineered strain of herpes simplex virus type 1. It is injected directly into accessible tumours, where the virus is intended to replicate selectively, destroy malignant cells and release tumour-associated antigens into the surrounding environment.
Replimune has armed the virus with granulocyte-macrophage colony-stimulating factor and a fusogenic protein known as GALV-GP R-. The company believes these additions increase direct tumour-cell killing, promote fusion between infected cells and stimulate a broader immune response against malignant cells elsewhere in the body.
The treatment is combined with nivolumab, an anti-PD-1 checkpoint inhibitor marketed as Opdivo. Nivolumab is intended to prevent tumour cells from suppressing activated immune cells, potentially allowing the immune response initiated by RP1 to continue attacking both injected and non-injected lesions.
The biological proposition is therefore more ambitious than local tumour destruction. Replimune must show that injecting selected lesions creates a systemic antitumour effect capable of shrinking cancer at distant sites.
That systemic contribution is also at the centre of the FDA disagreement. Regulators said that tumour shrinkage in injected lesions could represent a local procedural or viral effect without proving that the combination changes the broader course of the disease.
What did the 140-patient IGNYTE melanoma trial report?
The registration-intended IGNYTE cohort enrolled 140 patients with unresectable advanced melanoma that had progressed following anti-PD-1 therapy.
The population included clinically difficult cases. Nearly half had advanced stage IVM1b, IVM1c or IVM1d disease, approximately two-thirds had primary resistance to their earlier anti-PD-1 treatment and almost half had previously received both anti-PD-1 and anti-CTLA-4 therapy.
Replimune reported an independently assessed objective response rate of 33.6%, including a complete response rate of 16.4%. The company calculated a median response duration of 24.8 months in the regulatory dataset presented to the advisory committee.
Longer follow-up submitted by Replimune showed median overall survival of approximately 32.9 months. The reported one-year, two-year and three-year survival rates were 75.3%, 61.5% and 47.8%, respectively. These observations are potentially encouraging but come from a single-arm study, making it difficult to determine how patients would have performed under another treatment strategy.
The peer-reviewed IGNYTE publication described the responses as deep and durable and reported a generally manageable safety profile. Treatment-related adverse events were Grade 1 or Grade 2 in 77.1% of patients, Grade 3 in 9.3% and Grade 4 in 3.6%, with no Grade 5 treatment-related events in the published analysis.
Common lower-grade events included fatigue, chills, fever, nausea, influenza-like symptoms, injection-site pain, diarrhoea, vomiting, itching, muscle pain and reduced appetite. The overall tolerability profile could become an important differentiator if RP1 is approved for patients who are unable or unwilling to undergo more intensive cellular therapy.
Why did FDA reviewers dispute the reported RP1 response rate?
The FDA did not principally challenge whether tumours became smaller in some patients. Its concern was whether the study design and response-assessment methods allowed those changes to be attributed reliably to RP1.
IGNYTE was an open-label, single-arm trial without a concurrent nivolumab-only or physician’s-choice control group. The FDA said there was no dependable historical benchmark against which the reported response rate could be compared because patients who progress after anti-PD-1 therapy form a heterogeneous population with different prior treatments, disease burdens and resistance patterns.
The regulator also questioned how Response Evaluation Criteria in Solid Tumors, or RECIST, were applied to a treatment injected directly into tumours. RECIST was primarily developed for systemic therapies, where measurable lesions are observed without being physically injected or otherwise manipulated.
FDA reviewers argued that injected lesions could be difficult to evaluate because direct treatment may alter their appearance and size. They also said the analysis did not consistently separate injected and non-injected target lesions, limiting the ability to confirm whether RP1 produced systemic activity.
More than half of the patients classified as responders reportedly did not have a non-injected target lesion available for assessing systemic activity. When the FDA excluded certain patients without non-injected target lesions from its responder analysis, the lower boundary of the response-rate confidence interval declined to 10.1%.
The agency additionally raised concerns about patients continuing or restarting treatment after initial disease progression and about procedural removal of tissue affecting the apparent size of relatively small lesions.
Taken together, the FDA concluded that the reported response assessment could have artificially increased both the objective response rate and response duration. It also said the data could not establish how much of the observed benefit came from RP1 rather than nivolumab rechallenge.
Why did the advisory committee support RP1 despite the FDA’s objections?
The advisory committee’s favourable vote suggests that most members considered the totality of the evidence more persuasive than the FDA review team did.
Physicians and patients emphasised the unmet need among people whose melanoma has progressed after checkpoint-inhibitor treatment. Existing options can involve substantial toxicity, specialised infrastructure or surgical collection of tumour tissue.
Committee members also considered the depth and durability of the reported responses, the complete-response rate and evidence that some non-injected tumours became smaller. Replimune presented analyses indicating that injected and non-injected lesions showed similar response patterns, supporting its argument that RP1 activates systemic immunity rather than operating only at the injection site.
The panel’s question was carefully framed. Members were asked whether the IGNYTE results were evaluable and clinically meaningful, not whether the study represented an ideal randomised trial or whether approval was mandatory.
A committee member could therefore acknowledge methodological imperfections while concluding that the treatment produced genuine activity in a population with few satisfactory alternatives. The 10-to-three vote indicates that this clinical interpretation dominated the meeting even though the statistical and regulatory concerns were not eliminated.
How would RP1 compare with Amtagvi and other post-PD-1 melanoma options?
Iovance Biotherapeutics’ lifileucel, marketed as Amtagvi, is the principal FDA-authorised therapy specifically available after anti-PD-1 treatment in advanced melanoma.
Amtagvi is a tumour-infiltrating lymphocyte therapy. It requires surgical collection of tumour tissue, centralised cell manufacturing, lymphodepleting chemotherapy and interleukin-2 administration at an experienced treatment centre.
RP1 would follow a considerably different care model. It is administered through repeated intratumoral injections alongside nivolumab and would not require surgical tumour harvesting, personalised cell production or the same preparative chemotherapy regimen.
That could make RP1 accessible to patients who are not suitable for intensive cellular therapy or who live far from specialised treatment centres. The comparison remains indirect, however, because IGNYTE did not randomise patients against lifileucel or another established treatment.
The peer-reviewed IGNYTE report noted that lifileucel received accelerated approval with an objective response rate of approximately 31.4%. RP1’s company-reported response rate was similar numerically, but differences in eligibility criteria, patient characteristics and assessment methods prevent a reliable cross-trial conclusion that the treatments are equivalent.
Treatment selection could eventually depend on tumour accessibility, disease burden, the speed of progression, previous immunotherapy, patient fitness, treatment-centre availability and the durability established through longer follow-up.
Why is the randomised IGNYTE-3 confirmatory trial critical?
Replimune is already conducting the Phase 3 IGNYTE-3 trial comparing RP1 plus nivolumab with physician’s-choice treatment in advanced cutaneous melanoma.
The randomised study is intended to address the largest weakness in the accelerated-approval application: the absence of a concurrent control group. Its primary endpoint is overall survival, with response-related measures included as additional assessments.
An accelerated approval would probably be conditional on Replimune completing this trial and confirming clinical benefit. The FDA could withdraw the indication if the randomised evidence fails to verify benefit or if the company does not complete the required study with sufficient diligence.
IGNYTE-3 will also help clarify which patients benefit most. The single-arm study included patients with different prior checkpoint-inhibitor exposures, BRAF mutation statuses, disease burdens and patterns of resistance.
The randomised trial should provide a cleaner estimate of whether RP1 extends survival or improves outcomes compared with treatments physicians would otherwise select.
What could FDA approval or another rejection mean for Replimune?
Approval would transform Replimune from a clinical-stage biotechnology company into a commercial oncology business and provide the first regulatory validation of its RPx oncolytic-immunotherapy platform.
The company would still face a demanding launch. It would need to rebuild or expand commercial capabilities, train oncologists to identify and inject appropriate lesions, coordinate nivolumab use and ensure that treatment centres can manage both superficial and deeper tumour injections.
The eventual label could also be narrower than the company initially sought. The FDA may restrict treatment according to prior therapy, tumour accessibility, disease type or other characteristics and could require extensive post-market data.
Another complete response letter would raise more fundamental questions. If the agency concludes that IGNYTE cannot support accelerated approval despite the panel vote, Replimune may have to wait for randomised IGNYTE-3 results before returning to the regulator.
That would significantly extend the commercial timeline and preserve uncertainty around the company’s lead programme. It would also demonstrate that advisory-committee support cannot overcome an agency conclusion that the statutory effectiveness standard has not been met.
The panel improved RP1’s chances, but it did not repair the trial
The advisory committee vote materially improved Replimune’s regulatory position. Ten of 13 members concluded that the IGNYTE findings could be evaluated and were clinically meaningful, making a straightforward rejection more difficult for the FDA to explain.
Yet the panel did not retroactively turn IGNYTE into a randomised trial. Uncertainty remains over the true response benchmark, the contribution of nivolumab and whether the assessment of injected lesions inflated the apparent efficacy.
The strongest argument for approval is the combination of a meaningful reported response rate, durable complete responses, manageable toxicity and substantial unmet need. RP1 could offer a less operationally demanding option than tumour-infiltrating lymphocyte therapy for selected patients.
The strongest argument against approval is that accelerated approval still requires substantial evidence of effectiveness. Clinical urgency does not remove the need to determine whether RP1 itself caused the reported benefit.
A restricted accelerated approval tied firmly to the completion of IGNYTE-3 may represent the most balanced outcome. It would provide earlier access while requiring Replimune to confirm that the treatment improves outcomes in a controlled trial.
The delayed decision should not automatically be interpreted as positive or negative. Regulatory discussions may involve labelling, manufacturing, risk management or post-approval commitments, and none of those possibilities can be confirmed from investor commentary.
RP1 has passed the advisory committee test. The remaining question is whether the FDA believes the panel’s clinical judgement sufficiently offsets the evidentiary weaknesses identified by its own reviewers.
